Harrow Health, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Harrow Health, Inc. (HROW) holds an ST Score of 39.4 out of 100 (C), with its strongest factor being Forecast (A-) and its weakest Valuation (D). Analysts rate HROW Buy across 10 ratings with a $66.50 average price target (+1.0% vs the current $33.92).
- Strongest
- ForecastA-
- Weakest
- ValuationD
All factor grades
- ForecastA-
- ProfitabilityB-
- GrowthC-
- Financial StrengthD+
- MomentumD+
- ValuationD
- Piotroski4/9
Contact
HROW stock: frequently asked questions
What is HROW's ST Score?
Harrow Health, Inc. (HROW) has an ST Score of 39.4 out of 100, an overall grade of C. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is HROW a buy, sell, or hold?
Wall Street's consensus rating on HROW is Buy based on 10 analyst ratings. Our own ST Score grades it C (39.4/100). This is data, not investment advice — always do your own research.
What is HROW's valuation grade?
Harrow Health, Inc. (HROW) earns a valuation grade of D, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is HROW's growth grade?
Harrow Health, Inc. (HROW) earns a growth grade of C-, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is HROW's profitability grade?
Harrow Health, Inc. (HROW) earns a profitability grade of B-, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is HROW's financial strength grade?
Harrow Health, Inc. (HROW) earns a financial strength grade of D+, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for HROW?
The average analyst price target for Harrow Health, Inc. (HROW) is $66.50 from 10 analysts, which is +1.0% versus the recent price of $33.92.
What is HROW's Piotroski score?
Harrow Health, Inc. (HROW) has a Piotroski F-Score of 4 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.